Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 7/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9586237 | 0.93 | DHFR (0.59) | DHFRGHSR | |
| SCHEMBL9587848 | 0.93 | DHFR (0.57) | DHFR | |
| SCHEMBL9587570 | 0.91 | DHFR (0.57) | DHFRGHSR | |
| SCHEMBL9587214 | 0.91 | DHFR (0.57) | DHFRGHSR | |
| SCHEMBL9587910 | 0.90 | DHFR (0.47) | DHFRTYMS | |
| SCHEMBL9586972 | 0.89 | DHFR (0.55) | DHFRGHSR | |
| SCHEMBL9587800 | 0.89 | DHFR (0.70) | DHFR | |
| SCHEMBL9587038 | 0.89 | DHFR (0.53) | DHFR | |
| SCHEMBL9586768 | 0.89 | DHFR (0.54) | DHFRGHSR | |
| SCHEMBL9588498 | 0.88 | DHFR (0.60) | DHFRGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421118-A1 | A METHOD FOR THE TREATMENT OR PREVENTION OF BONE EROSION | Sankyo Company Limited (JP) | 2004-05-26 | — | — | EP | claimed |
| WO-2003020768-A1 | A METHOD FOR THE TREATMENT OR PREVENTION OF BONE EROSION | SANKYO COMPANY, LIMITED (JP) | 2003-03-13 | — | — | WO | claimed |
| US-20020103212-A1 | Pharmaceutical compositions containing anti-fas antibody | SANKYO COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | claimed |
| EP-1180369-A1 | MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY | Sankyo Company, Limited (JP) | 2002-02-20 | — | — | EP | claimed |
| US-7981421-B2 | Combinations of antibodies selective for DR5 and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110002887-A1 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR DR5 AND OTHER THERAPEUTIC AGENTS | THE UAB RESEARCH FOUNDATION (US) | 2011-01-06 | — | — | US | disclosed |
| EP-1506285-B1 | COMBINATIONS OF ANTI-DR5 ANTIBODIES AND ANTI-DR4 ANTIBODIES AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7704502-B2 | Combinations of antibodies selective for DR5 and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090022707-A1 | Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents | THE UAB RESEARCH FOUNDATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-7279160-B2 | Combinations of DR5 antibodies and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1506285-A4 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1506285-A2 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6746673-B2 | FOR PROPHYLAXIS AND/OR TREATMENT OF AN AUTOIMMUNE DISEASE OR RHEUMATOID ARTHRITIS | SANKYO COMPANY, LIMITED (JP) | 2004-06-08 | — | — | US | disclosed |
| EP-1421118-A1 | A METHOD FOR THE TREATMENT OR PREVENTION OF BONE EROSION | Sankyo Company Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20030133932-A1 | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | UAB RESEARCH FOUNDATION, THE | 2003-07-17 | — | — | US | disclosed |
| WO-2003038043-A2 | COMBINATIONS OF DR5 ANTIBODY AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003020768-A1 | A METHOD FOR THE TREATMENT OR PREVENTION OF BONE EROSION | SANKYO COMPANY, LIMITED (JP) | 2003-03-13 | — | — | WO | disclosed |
| US-20020103212-A1 | Pharmaceutical compositions containing anti-fas antibody | SANKYO COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
| EP-1180369-A1 | MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY | Sankyo Company, Limited (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-1993013079-A1 | ANTIFOLATE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103212-A1 | Pharmaceutical compositions containing anti-fas antibody | DHFR, FOLR1, FOLR2 | DHFR 1/4885GHSR 4653/4885TYMS 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.